A

Adocia SA
PAR:ADOC

Watchlist Manager
Adocia SA
PAR:ADOC
Watchlist
Price: 6.57 EUR 1.86% Market Closed
Market Cap: 120.3m EUR

Adocia SA
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Adocia SA
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
A
Adocia SA
PAR:ADOC
Cash from Operating Activities
-€15.3m
CAGR 3-Years
8%
CAGR 5-Years
N/A
CAGR 10-Years
-8%
Valneva SE
PAR:VLA
Cash from Operating Activities
-€11.9m
CAGR 3-Years
52%
CAGR 5-Years
N/A
CAGR 10-Years
4%
Nanobiotix SA
PAR:NANO
Cash from Operating Activities
-€31.2m
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
-10%
Inventiva SA
PAR:IVA
Cash from Operating Activities
-€162m
CAGR 3-Years
-37%
CAGR 5-Years
-53%
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
Cash from Operating Activities
-$87m
CAGR 3-Years
-116%
CAGR 5-Years
8%
CAGR 10-Years
-14%
Abivax SA
PAR:ABVX
Cash from Operating Activities
-€187m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Adocia SA
Glance View

Market Cap
118.3m EUR
Industry
Biotechnology

Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.

ADOC Intrinsic Value
HIDDEN
Show

See Also

What is Adocia SA's Cash from Operating Activities?
Cash from Operating Activities
-15.3m EUR

Based on the financial report for Jun 30, 2025, Adocia SA's Cash from Operating Activities amounts to -15.3m EUR.

What is Adocia SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-8%

Over the last year, the Cash from Operating Activities growth was -31%. The average annual Cash from Operating Activities growth rates for Adocia SA have been 8% over the past three years , and -8% over the past ten years .

Back to Top